• Pharming Group NV posted a net loss of US$5.2 million, narrowing from a year-earlier net loss, as revenue fell 8% to US$72.4 million.
• Operating loss narrowed to US$4.9 million, while RUCONEST revenue dropped 15% to US$58.4 million on specialty pharmacy inventory drawdowns and a planned exit from non-U.S. markets.
• Joenja revenue climbed 34% to US$14.1 million, with 127 patients on paid therapy in the U.S. as of March 31.
• Joenja gained approval in Japan for APDS patients aged 4 and older, while a positive CHMP opinion in Europe sets up an expected European Commission decision in Q2.
• Pharming reaffirmed 2026 revenue guidance of US$405 million-US$425 million, flagging quarterly fluctuations and progress toward Joenja pediatric label expansion in the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070100PRIMZONEFULLFEED1001180419) on May 07, 2026, and is solely responsible for the information contained therein.